

Epidemiological, clinical, biological and therapeutic profile of bacterial meningitis and factors associated with lethality: a retrospective study in the Fann Infectious and Tropical Diseases Service (2020-2023)

Abstract

Introduction

Bacterial meningitis remains a major public health problem in Africa, with a persistently high incidence and case fatality. The objective of this study is to describe the epidemiological, clinical, biological and therapeutic profile of bacterial meningitis, and to identify the factors associated with lethality.

Patients and method

A descriptive and analytical retrospective study was conducted from the records of patients hospitalized for bacterial meningitis at the SMIT in Fann between January 2020 and December 2023. A multivariate regression, with a significance threshold set at 5%, was performed using R software version 4.2.0.

Results

During the study period, we collected 138 inpatient records of patients hospitalised for bacterial meningitis, representing a hospital frequency of 3.06%.

The median age of patients was 35 years with IQC [27-52]. HIV infection (17.39%), high blood pressure (8.76%) and diabetes (8.03%) were the most common comorbidities. Cerebrospinal fluid (CSF) was clear in nearly half of the cases (49.28%), and cytology found a predominantly polynuclear neutrophil white blood cell count in 50% of cases. The median length of hospital stay was 10 days with IQI [7-17]. During hospitalization, 49 patients had died, i.e., a case fatality rate of 35.51%.

Factors associated with death were HIV infection (aOR= 3.09; 95% CI [1.05-9.57]), Glasgow score < 13 (aOR: 3.62; 95% CI [1.57-8.57]) and CRP > 96 mg/L (aOR: 2.85; 95% CI [1.25-6.72]).

Conclusion

Bacterial meningitis has a high lethality rate at Fann's SMIT. Improving immunization coverage, strengthening diagnostic capacity and early management could reduce this fatality.

Introduction

Bacterial meningitis remains a global public health problem[1]. These are serious infections of the central nervous system that are life-threatening and with a poor functional prognosis. In 2019, there were an estimated 2.51 million new cases worldwide, with an estimated 236,000 deaths[2]. Despite the efforts made, especially with vaccination, Africa is the continent most affected by meningitis with incidence rates ranging from 87.2 to 105.8 cases per 100,000 inhabitants[2]. Mortality in this continent remains the highest in the world with rates of up to 18.4 per 100,000 inhabitants. Various factors can explain this high morbidity and mortality in Africa: climatic conditions, low vaccination rates, migration and displacement, limited access to health care, antibiotic resistance and poor socio-economic conditions[3–5].

In Senegal, the Infectious and Tropical Diseases Department (SMIT) of the CHUN de Fann, located in Dakar, is the main referral centre for the management of meningitis in adults. The studies conducted so far at this department have generally been oriented towards a specific aetiology [6–8]. The most comprehensive study was published in 2005 and focused on neuromeningeal infections; These conditions accounted for 11.4% of new admissions, with a high case fatality rate of 44.5%[9]. To our knowledge, few studies conducted in the department on bacterial meningitis and the factors influencing its lethality have been found in the literature. This study aims to describe the epidemiological, clinical, biological and therapeutic profile of bacterial meningitis, and to identify the factors associated with death.

Materials and methods

Type and period of study

This was a retrospective, descriptive and analytical study, carried out from the hospital records of patients admitted to the infectious diseases department of the Fann University Hospital in Dakar, from January 1, 2020 to December 31, 2023. All patients hospitalized for bacterial meningitis (after biochemical and/or bacteriological analysis of CSF) were included. Bacterial meningitis

was defined by a cellularity of more than 10 white blood cells/mm³ associated with CSF glucose levels < 0.5 g/l with or without bacterial isolation on CSF examination.

Data collection

Data were collected from patients' medical records, using a survey sheet, that was developed based on a literature review. Data were then entered into Microsoft Excel before being exported to R software. They included epidemiological (date of hospitalization, age, sex, geographical origin, marital status), clinical (lifestyle, vaccination status, comorbidities, symptoms and signs), laboratory (CBC, CRP, biochemical and bacteriological analysis of CSF), therapeutic (antibiotics used, adjuvant measures), and evolutionary (length of hospitalization, lethality) characteristics.

Statistical analyses

Qualitative variables were expressed as a proportion and quantitative variables as a mean with standard deviation (in the case of a normal distribution) or as a median with interquartile ranges (in the case of a non-normal distribution). Factors associated with lethality were assessed using multivariate logistic regression, adjusted according to relevant confounding factors: age, comorbidities, duration of evolution of symptoms, Glasgow coma score, focal neurological signs, C-Reactive protein. P values less than 0.05 were considered statistically significant. We reported the effect of variables as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical analyses were carried out using the R studio software, version 4.4.0.

Ethical considerations

All data collected were treated confidentially and anonymously. Prior authorization from the head of the infectious and tropical diseases department was obtained.

Results

Epidemiological data

During the study period, we collected 138 cases of bacterial meningitis out of a total of 4222 admissions, i.e., a hospital frequency of 3.06%. The monthly distribution of cases showed peaks during the months of January and February (Figure 1). A male predominance was noted with a sex ratio of 1.3 and the median age of patients was 35 years with an interquartile range (IQR) of

[27-52] years. The most represented age group was 20-40 years old representing 46.37% of cases. Nearly half of the patients came from the peri-urban area of Dakar (46.38%), followed by the urban area (34.78%). HIV infection (17.4%), high blood pressure (8.8%) and diabetes (8.03%) were the main comorbidities found. Only 3 patients had an up-to-date vaccination status. Pre-hospitalization antibiotic use was reported in 41.3% of patients.

Clinical data

Headache was the main reason for consultation, present in 73.91% of patients (Figure 2). This was accompanied by vomiting in 33.33% of cases. The most common physical signs were those of meningeal irritation: stiff neck (88.41%), Kernig's sign (66.67%), Brudzinski's sign (63.04%). More than 10% of patients showed focal neurologic signs, and 8.70% had seizures.

Laboratory data

We found a non-specific inflammatory reaction with C-reactive protein (CRP) greater than 96 mg/l in one third of patients (33.33%) and 38.54% of patients had elevated white cell count ($> 12,000$ cells/mm³).

CSF was clear in 49.28% of cases and cloudy in 36.23%. Pleiocytosis was predominantly polynuclear neutrophils, impaired and unaltered in 50%. The majority of patients (96.35%) presented with elevated CSF protein. CSF microscopy and culture were performed on all patient specimens. In 85.51% of cases, no germs were found. Thus, direct examination, soluble antigen testing and culture were positive in only 13 cases, including 8 cases of *Mycobacterium tuberculosis* identified by the Xpert/MTB-Rif test, 3 cases of *Streptococcus pneumoniae* and 2 cases of *Neisseria meningitidis* isolated (Table I).

Brain CT scan performed in 16 patients showed mainly ischemia (5 cases), hydrocephalus (4 cases), and sinusitis lesions (3 cases). There was no expansive brain lesion, no mass effect, no peripheral contrast intake.

Therapeutic and evolutionary aspects

The most commonly used antibiotic was ceftriaxone, which was administered to 92.04% of patients, either alone or in combination with other antibiotics, such as gentamicin (86.21%) or

vancomycin (47.06%). Approximately 35.51% of patients received quadruple anti-tuberculosis therapy. Adjuvant corticosteroid therapy was administered to 48.55% of patients, particularly in those with tuberculous meningitis, prednisone was the most commonly used corticosteroid (31.16%). The median length of hospital stay was 10 days, with an interquartile range (IQR) of [7-17] days. The case fatality rate was 35.51% (49 patients).

Factors associated with the lethality of acute bacterial meningitis

After multivariate logistic regression, HIV infection (aOR = 3.09; 95% CI [1.05-9.57]), Glasgow Coma score < 13 (aOR: 3.62; 95% CI [1.57-8.57]) and CRP > 96 mg/L (aOR: 2.85; 95% CI [1.25-6.72]) were the factors associated with case fatality (Table III).

Discussion

The study has some limitations, particularly its retrospective nature, which led to missing data for some variables. In addition, since the study is single-centre and based solely on hospital data, we could not statistically generalize the results to the entire Senegalese population. However, the results obtained can be compared with the data in the literature.

In our study, the in-hospital frequency of bacterial meningitis was 3.06% with a predominance of cases observed in January and February. This seasonal variation has also been reported in several studies[10,11]. The hypothesis that dust particles damage the pharyngeal mucosa, thus facilitating bacterial invasion, is possible. In recent years, much research has focused on exploring the link between bacterial meningitis and climatic conditions[11]. The median age of 35 years and the 20-40 years age group being the most represented, reflect trends observed around the world.

Although bacterial meningitis affects people of all ages, young children and young adults are most at risk[12]. In addition, the SMIT being a department dedicated to the care of adults, may explain this demographic profile. As far as vaccination coverage is concerned, vaccination rates were very low (2.17%) in our study. This result is in agreement with the work of Dollo et al. in Mali, where the vaccination status was unknown for all cases[13] and a study by Merabet et al. in Morocco, where the vaccination rate was 5.57%[14].

The clinical profile observed in this study is marked by fever (52.55%), headache (73.91%), stiff neck (88.41%) and Kernig's sign (66.67%). These features are consistent with clinical

descriptions reported in previous studies, including those of Tekpa et al., where fever, headache, and Kernig's sign were also among the most frequently observed manifestations [14,15]. More than 10% of patients showed focal neurological signs. The presence of focal neurologic signs suggest damage to the cerebral parenchyma, which may characterize encephalitis or cerebral abscesses, especially when the presumed etiology is *Streptococcus pneumoniae*. Thus, CT scans were performed to look for these abnormalities and revealed cases of ischemia (5 cases) and hydrocephalus (4 cases). Our data are comparable to those reported in the literature, where focal neurologic signs are associated with severe meningeal involvement[16,17].

Macroscopically, nearly half of the cases (49.28%) had clear cerebrospinal fluid, while more than one in three patients (36.23%) had cloudy CSF. The clarity of CSF could be attributed either to prior antibiotic therapy or to clear-fluid bacterial meningitis such as tuberculous meningitis. On the other hand, the abnormalities typical of bacterial meningitis, such as the predominance of polynuclear cells and elevated CSF protein, were found. However, the microbiological identification of pathogens was a major challenge in our study, with 85.51% of samples detecting no germs. This finding is consistent with the results of an earlier study conducted in the same department, where 72% of the etiologies of neurological infections remained unknown[18]. Similarly, in Cameroon, among 742 cerebrospinal fluid samples analysed in patients with clinical signs of meningitis, only 9.57% revealed a germ[19]. These results highlight the difficulties encountered in the detection of pathogens, often due to an inadequate technical platform. For this reason, several studies have validated polymerase chain reaction (PCR) tests to diagnose bacterial meningitis. This work shows that PCR can overcome the limitations of conventional methods[20–23]. However, the use of antibiotics before hospitalization, reported in 41.3% of our patients, may also explain this high rate of CSF culture negativity. With 58.2% of antibiotic therapy before admission, Coulibaly DS et al made the same observation[24].

Regarding treatment, ceftriaxone remains the reference antibiotic in our study, despite the frequent lack of formal identification of pathogens. It is an empirical approach that reflects practices in resource-limited settings, where etiological diagnosis often remains inaccessible. In accordance with current recommendations, the choice of initial treatment is by necessity empirical and probabilistic in view of the severity of any delay in care[25]. In our patients who

presented with signs of sepsis associated with meningitis, gentamicin was most frequently associated (86.21%) with ceftriaxone in their management.

Prognostically, the lethality reported in our study remains relatively high at 35.51 percent. Poor prognostic factors were HIV infection, a Glasgow coma score < 13 and a CRP level > 96 mg/L.

During HIV infection, neurologic pathologies are common and can occur at all stages of infection. Regardless of their etiology, they increase the risk of serious neurological complications and death, as shown in our study and other similar studies [26,27].

Coma is a sign of poor prognosis in cases of bacterial meningitis. Other studies have also found such an association [28–30]. This is the consequence of an excessive inflammatory response, thus leading to neurological damage [31]. The main causes of coma are: cerebral edema, convulsions and cerebrovascular lesions [32]. Alterations of consciousness may indicate a delay in diagnosis and treatment, hence the interest in rapid initial management of meningitis cases [33].

Other authors had reported similar results, pointing to elevated CRP as a factor associated with death [34,35]. The morbidity and mortality of meningitis are due to an uncontrolled inflammatory response of the host, especially at the level of neurons, leading to fatal complications [36]. This might explain why CRP being an inflammatory marker would be elevated in fatal cases of bacterial meningitis. Elevated CRP levels can also be due to sepsis as part of a general complication, responsible for multiorgan failure [37].

Conclusion

This study highlights the high mortality associated with bacterial meningitis, with insufficient vaccination coverage. The clinical profile observed is in line with those reported in the literature, but the microbiological identification of pathogens remains a major challenge. Finally, the poor prognostic factors identified include HIV infection, a Glasgow score below 13 and a high CRP. These results highlight the importance of early management and strengthening of prevention strategies in the field of vaccination and the improvement of technical platforms for more important etiological research.

Tables and figures




Figure 1: Distribution by month of patients hospitalized for bacterial meningitis at SMIT, Fann from 2020 to 2023




Figure 2 : Distribution by neurological signs of patients hospitalized for bacterial meningitis at SMIT, Fann from 2020 to 2023

Table I: Distribution by CSF examination results of patients hospitalized for bacterial meningitis at SMIT, Fann from 2020 to 2023

CSF Features	Absolute Frequency (N)	Relative Frequency (%)
Macroscopy		
Clear	68	49,28
Cloudy	50	36,23
Xanthochromic	9	6,52
Hematic	2	1,45
Cytology	9	6,52
Polynuclear predominance	50	50
Lymphocyte predominance	49	49
Variegated	1	1
Biochemistry		
Low Glucose	138	100
High protein	133	96,35
Bacteriological examination of CSF		
Germes not detected	118	85,51
<i>Mycobacterium tuberculosis</i>	8	5,80
<i>Staphylococcus saprophyticus</i>	4	2,90
<i>Neisseria meningitidis</i>	2	1,45
<i>Staphylococcus aureus</i>	2	1,45
<i>Streptococcus pneumoniae</i>	3	2,17
<i>Haemophilus influenzae</i>	1	0,72

Table II: Predictive factors for death of patients hospitalized for bacterial meningitis at SMIT, Fann from 2020 to 2023

Characteristics	Univariate			Multivariate		
	OR1	95% CI1	p-value	OR1	95% CI1	p-value
Age > 65 years	1.21	0.60, 2.44	0.59	0.90	0.39, 2.05	0.8
Focal signs	1.98	0.68, 5.74	0.21	1.44	0.43, 4.79	0.5
HIV infection	3.92	1.59, 10.2	0.003	3.09	1.05, 9.57	0.041
Glasgow coma score < 13	4.72	2.24, 10.3	<0.001	3.62	1.57, 8.57	0.003
CRP >96 mg/l	2.46	1.21, 5.09	0.013	2.85	1.25, 6.72	0.013
Symptoms > 21 days	1.58	0.76, 3.28	0.22	1.74	0.76, 4.04	0.2

¹OR = Odds Ratio, CI = Confidence Interval

References

1. Meningococcal meningitis [Internet]. [cited 2024 Nov 30]. Available on: <https://www.who.int/fr/news-room/fact-sheets/detail/meningitis>
2. Wunrow HY, Bender RG, Vongpradith A, Sirota SB, Swetschinski LR, Novotney A, et al. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol* [Internet]. 1 août 2023 [cité 30 nov 2024]; 22(8):685-711.
3. Rezaei SJ, Mateen FJ. Encephalitis and meningitis in Western Africa: a scoping review of pathogens. *Trop Med Int Health TM IH*. avr 2021; 26(4):388-96.
4. Mazamay S, Guégan JF, Diallo N, Bompangue D, Bokabo E, Muyembe JJ, et al. An overview of bacterial meningitis epidemics in Africa from 1928 to 2018 with a focus on

epidemics “outside-the-belt”. *BMC Infect Dis* [Internet]. 30 sept 2021 [cité 8 avr 2024]; 21(1):1027.

5. Boucher A, Herrmann JL, Morand P, Buzelé R, Crabol Y, Stahl JP, et al. Epidemiology of infectious encephalitis causes in 2016. *Med Mal Infect*. mai 2017; 47(3):221-35.
6. Seydi M, Soumaré M, Sow AI, Diop BM, Sow PS. [Escherichia coli meningitis during bacteremia in the Ibrahima-Diop-Mar infectious diseases clinic, Dakar Fann National Hospital Center (Senegal)]. *Med Mal Infect* [Internet]. 1 juin 2005 [cité 15 janv 2025]; 35(6):344-8.
7. Manga NM, Ndour CT, Diop SA, Ka-Sall R, Dia NM, Seydi M, et al. [Adult purulent meningitis caused by Streptococcus pneumoniae in Dakar, Senegal]. *Med Trop (Mars)*. 1 déc 2008; 68(6):625-8.
8. Soumare M, Seydi M, Ndour CT, Dieng Y, Ngom-Faye NF, Fall N, et al. [Clear-fluid meningitis in HIV-infected patients in Dakar]. *Bull Soc Pathol Exot* 1990. 1 juin 2005; 98(2):104-7.
9. Soumaré M, Seydi M, Ndour CT, Fall N, Dieng Y, Sow AI, et al. [Epidemiological, clinical, etiological features of neuromeningeal diseases at the Fann Hospital Infectious Diseases Clinic, Dakar (Senegal)]. *Med Mal Infect*. 2005; 35(7-8):383-9.
10. Terwin K, Ferreira M, Minnie C, Marangellis K, Darby R, Berlyn J, et al. The epidemiological profile of meningitis among adults in a South African district hospital. *Pan Afr Med J*. 2022;41:256.
11. Agier L, Deroubaix A, Martiny N, Yaka P, Djibo A, Broutin H. Seasonality of meningitis in Africa and climate forcing: aerosols stand out. *J R Soc Interface*. févr 2013; 10(79):20120814.
12. Lalande V, Schnuriger A. Meningitis and infectious encephalitis: diagnosis, complementary analyses and syndromic approach. *Rev Francoph Lab* [Internet]. 2023 Jul 1 [cited 2024 Dec 1]; 2023(554):27-37.
13. Dollo I, Touré YA, Mariko S, Dao K, Traoré AM, Touré K, et al. Meningococcal C Meningitis in the Artisanal Gold-Panning Zone of N'tahaka, Gao Region. *Health Res Afr* [Internet]. 26 juin 2024 [cité 1 déc 2024]; 2(7).
14. Merabet M, Aouragh R, Idrissi A. Community-based acute bacterial meningitis in children under 5 years of age in the Tangier-Tetouan-Al Hoceima region (Morocco) 2006-2015: epidemiological, clinical and biological profile. *Antropo* [Internet]. 2018 [cited 2024 Dec 1]; (40):1-11.

15. Tekpa G, Ngai EG, Yangatimbi E, Kitakossi F, Mossoro-kpinde CD, Mbelesso P. Clinical and bacteriological aspects of purulent meningitis in rural Central African Republic. *Rev Malian Infect Microbiol* [Internet]. 2020 May 14 [cited 2024 Dec 1]; 15(1):44-53.
16. Hermann B, Simony M, Rohaut B. Disorders of consciousness, coma. *Emc – Neurol* [Internet]. Jul 2023 [cited 2025 Jan 13]; 46(3):1-16.
17. Bernard-Valnet R. Central nervous system infections: a toolbox for general practitioners. *Rev Médicale Suisse* [Internet]. 2022 [cited 2025 Jan 13]; 18(779):863-4.
18. Ka D, Fall NM, Diallo-Mbaye K, Thiam FB, Dia A, Ndiaye R, et al. Prevalence and Factors Associated with Infectious Meningitis and Meningoencephalitis Related Deaths in People Living with HIV (PLHIV). *J Infect Dis Ther* [Internet]. 9 nov 2019 [cité 1 déc 2024];2019.
19. Graobe BB, Gake B, Bamia A, Gake NM, Seukap EC, Mballa AE, et al. Etiological Agents of Meningitis in Northern Cameroun: a Retrospective Study from Patients Suspected of Meningitis Enrolled in Case by Case Based Surveillance after MenAfriVac. *Health Sci Dis* [Internet]. 30 mars 2023 [cité 1 déc 2024]; 24(4).
20. Sharma N, Gautam H, Tyagi S, Raza S, Mohapatra S, Sood S, et al. Clinical use of multiplex-PCR for the diagnosis of acute bacterial meningitis. *J Fam Med Prim Care* [Internet]. févr 2022 [cité 10 janv 2025]; 11(2):593.
21. Diallo K, Fetei VF, Ibe L, Antonio M, Caugant DA, Plessis M du, et al. Molecular diagnostic assays for the detection of common bacterial meningitis pathogens: A narrative review. *eBioMedicine* [Internet]. 1 mars 2021 [cité 10 janv 2025];65.
22. Albuquerque RC, Moreno ACR, dos Santos SR, Ragazzi SLB, Martinez MB. Multiplex-PCR for diagnosis of bacterial meningitis. *Braz J Microbiol* [Internet]. 1 avr 2019 [cité 10 janv 2025]; 50(2):435-43. Disponible sur: <https://doi.org/10.1007/s42770-019-00055-9>
23. Carnalla-Barajas MN, Soto-Noguerón A, Martínez-Medina L, Olvera-Herrera ME, Mosqueda-Gómez JL, Rodríguez-Cortez P, et al. Diagnosis of bacterial meningitis caused by *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* using a multiplex real-time PCR technique. *Braz J Microbiol* [Internet]. 1 déc 2022 [cité 10 janv 2025]; 53(4):1951-8.
24. Coulibaly DS, Samake D, Traore M, Goita D, Cissoko Y, Dao S. Etiologies of Meningeal Disorders in the Infectious Diseases Department of the CHU-Point-G (Bamako). *Health Sci Dis* [Internet]. 2020 May 20 [cited 2024 Dec 1]; 21(6).

25. Gillet Y, Grimprel E, Haas H, Yaghy M, Dubos F, Cohen R. Antibiotic therapy for bacterial meningitis. *J Pediatrics and Childcare* [Internet]. 2024 Jun 1 [cited 2024 Dec 1]; 37(3):182-9.
26. Rolland OIB, Obengui, Bébene DB, Macaire ONP, Herdan P, Claude BPJ, et al. Neuromeningeal disorders during HIV in the infectious diseases department of the Brazzaville University Hospital: prevalence and factors associated with death. *Eur Sci J ESJ* [Internet]. 2016 Nov 30 [cited 2025 Jan 10]; 12(33):177-177.
27. Diop M, Al E. Central nervous system infections: Etiological profile and factors associated with death in the infectious and tropical diseases department of the Principal Hospital of Dakar, Senegal. *Rev Malian Infect Microbiol* [Internet]. 2024 Oct 16 [cited 2025 Jan 10]; 19(3):12-9.
28. Ammouri W, Dendane T, Abidi K, Madani N, Abouqal R, Zeggwagh AA. Prognostic factors for community-acquired bacterial meningitis in intensive care. *Maroc Med* [Internet]. 2010 [cited 2024 Oct 29]; 32(2).
29. Beek D van de, Gans J de, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical Features and Prognostic Factors in Adults with Bacterial Meningitis. *N Engl J Med* [Internet]. 28 oct 2004 [cité 29 oct 2024]; 351(18):1849-59.
30. Sunwoo JS, Shin HR, Lee HS, Moon J, Lee ST, Jung KH, et al. A hospital-based study on etiology and prognosis of bacterial meningitis in adults. *Sci Rep*. 16 mars 2021; 11(1):6028.
31. Poulsen FR, Schulz M, Jacobsen A, Andersen ÅB, Larsen L, Schalén W, et al. Bedside evaluation of cerebral energy metabolism in severe community-acquired bacterial meningitis. *Neurocrit Care*. avr 2015; 22(2):221-8.
32. Sonnevile R, Citerio G, Meyfroidt G. Understanding coma in bacterial meningitis. *Intensive Care Med*. août 2016; 42(8):1282-5.
33. Beek D van de, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. *Clin Microbiol Infect* [Internet]. 1 mai 2016 [cité 29 oct 2024]; 22:S37-62.
34. Hsu CL, Chang CH, Wong KN, Chen KY, Yu CJ, Yang PC. Management of Severe Community-acquired Septic Meningitis in Adults: From Emergency Department to Intensive Care Unit. *J Formos Med Assoc* [Internet]. 1 févr 2009 [cité 29 oct 2024]; 108(2):112-8.
35. Chekrouni N, Kroon M, Drost EHGM, van Soest TM, Bijlsma MW, Brouwer MC, et al. Characteristics and prognostic factors of bacterial meningitis in the intensive care unit: a prospective nationwide cohort study. *Ann Intensive Care*. 6 déc 2023; 13(1):124.

36. Koelman DLH, Brouwer MC, van de Beek D. Targeting the complement system in bacterial meningitis. *Brain J Neurol.* 1 nov 2019; 142(11):3325-37.

37. Ciapponi A, Elorriaga N, Rojas JI, Romano M, Martí SG, Bardach A, et al. Epidemiology of pediatric pneumococcal meningitis and bacteremia in Latin America and the Caribbean: a systematic review and meta-analysis. *Pediatr Infect Dis J.* sept 2014; 33(9):971-8.

UNDER PEER REVIEW